Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 12, 2013, Pages 1345-1351

  Poon, Ken Shing Ho ^a,b   Un, Man Kit ^a,b   Low, Xiu Hui ^a   Cheung, Yin Ting ^a,d   Yap, Kevin Yi Lwern ^a,c   Chan, Alexandre ^a,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Anticancer treatment; Anxiety; Cancer; Chemotherapy; Fatigue; Nausea and vomiting; Pharmacoepidemiology

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; DOXORUBICIN; EPIRUBICIN; OXALIPLATIN;

ADULT; ARTICLE; ASIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PATIENT; CANCER RISK; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DAILY LIFE ACTIVITY; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; FEMALE; HEAD AND NECK CANCER; HUMAN; LIKERT SCALE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM;

ANTICANCER TREATMENT; ANXIETY; CANCER; CHEMOTHERAPY; FATIGUE; NAUSEA AND VOMITING; PHARMACOEPIDEMIOLOGY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FATIGUE; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGAPORE; VOMITING;

EID: 84888434055     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3516     Document Type: Article

References (33)

1. Stieler JM, Reichardt P, Riess H, Oettle H. Treatment options for chemotherapy-induced nausea and vomiting: current and future. Am J Cancer 2003; 2: 15-26.
2. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist 1999; 4: 191-196.
3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Antiemesis v.1. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf [17 January 2013].
4. Andrykowski MA. The role of anxiety in the development of anticipatory nausea in cancer chemotherapy: a review and synthesis. Psychosom Med 1990; 52: 458-475.
5. Morrow GR, Lindke JL, Black PM. Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics. J Pain Symptom Manage 1991; 6: 215-223.
6. Spiess JL, Adelstein DJ, Hines JD. Evaluation of ethanol as an antiemetic in patients receiving cisplatin. Clin Ther 1987; 9: 400-404.
7. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 1997; 15: 116-123.
8. Warr DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 2011; 19: 807-813.
9. Molassiotis A, Yam BMC, Yung H, Chan FYS, Mok TSK. Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 2002; 10: 139-145.
10. Shih V, Wan HS, Chan A. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Ann Pharmacother 2009; 43: 444-452.
11. Navari RM. Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2006; 2: 591-602.
12. Hofman M, Ryan JL, Colmar DF-M, Pascal J-P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist 2007; 12: 4-10.
13. Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center-Community Clinical Oncology Program study of 938 patients from community practices. Cancer 2004; 101: 851-857.
14. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the fatigue coalition. Oncologist 2000; 5: 353-360.
15. Morrow GR, Andrews PLR, Hickok JT, Roscoe JA, Matteson S. Fatigue associated with cancer and its treatment. Support Care Cancer 2002; 10: 389-398.
16. Díaz N, Menjón S, Rolfo C, et al. Patients' perception of cancer-related fatigue: results of a survey to assess the impact on their everyday life. Clin Transl Oncol 2008; 10: 753-757.
17. Yap KY, Low XH, Chan A. Exploring chemotherapy-induced toxicities through multivariate projection of risk factors: prediction of nausea and vomiting. Toxicol Res 2012; 28: 81-91.
18. Chan A, Low XH, Yap KY. Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. J Manag Care Pharm 2012; 18: 385-394.
19. Yap KYL, Low XH, Chui WK, Chan A. Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting. J Clin Psychopharmacol 2012; 32: 207-217.
20. Gralla RJ, De Wit R, Herrstedt J, et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 2005; 104: 864-868.
21. Barnes EA, Bruera E. Fatigue in patients with advanced cancer: a review. Int J Gynecol Cancer 2002; 12: 424-428.
22. Goedendorp MM, Gielissen MFM, Verhagen C., Bleijenberg G. Development of fatigue in cancer survivors: a prospective follow-up study from diagnosis into the year after treatment. J Pain Symptom Manage 2013; 45: 213-222.
23. Goldstein D, Bennett BK, Webber K, et al. Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study. J Clin Oncol 2012; 30: 1805-1812.
24. Mota DDCF, Pimenta CAM, Caponero R. Fatigue in colorectal cancer patients: prevalence and associated factors. Rev Lat Am Enfermagem 2012; 20: 495-503.
25. Paiva CE, Paiva BSR. Prevalence, predictors, and prognostic impact of fatigue among Brazilian outpatients with advanced cancers. Support Care Cancer 2013; 21(4): 1053-1060.
26. Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: a critical appraisal. Eur J Cancer 2006; 42: 846-863.
27. Seo Y, Oh H, Seo W. Causal relationships among factors associated with cancer-related fatigue. Eur J Oncol Nurs 2010; 14: 380-386.
28. Cheung YT, Maung Shwe HG, Tan YP, Fan GKT, Ng RCH, Chan A. Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. Ann Oncol 2012; 23: 2547-2552.
29. Hökfelt T, Bartfai T, Bloom F. Neuropeptides: opportunities for drug discovery. Lancet Neurol 2003; 2: 463-472.
30. Muñoz M, Coveñas R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr Med Chem 2011; 18: 1820-1831.
31. Yennurajalingam S, Reuben JM, Palmer JL, et al. Cancer-related-fatigue (CRF) is associated with IL-6, IL-6R and IL-17, while IL-8 and IL-6 are associated with no improvement of CRF after treatment. Support Care Cancer 2011; 19: S233.
32. Basch E, Artz D, Dulko D, et al. Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2005; 23: 3552-3561.
33. Seyidova-Khoshknabi D, Davis MP, Walsh D. A systematic review of cancer-related fatigue measurement questionnaires. Am J Hosp Palliat Care 2011; 28: 119-129.